Sentences with phrase «drug research company»

Not exact matches

Drug giant GlaxoSmithKline's head of research and development, Patrick Vallance, is departing the company to head over to the U.K. public sector.

Drug manufacturing and research companies are in a merger frenzy.

That research will be crucial: An earlier effort by another company, Pathway Genomics, to create a «liquid biopsy» for cancer was greeted in September by a stern letter from the Food and Drug Administration (FDA) warning that the agency had «not found any published evidence that this test or any similar test has been clinically validated as a screening tool for early detection of cancer in high risk individuals.»

«Shoppers tends to be a Top Five company, but last year was a low point for them with the fight for generic drugs,» says Susan Quinn - Mullins, a senior adviser to the Research Institute.

Cummings: The research has shown, first of all, that whenever [Congress] shine a light on prescription - drug companies with regard to price hikes automatically they have a tendency to slow down the rate of price hikes.

Recent Projects: researching number of burglar - alarm systems installed in homes and businesses (three hours» work, $ 250); pricing new drug for pharmaceutical company.

This government cash helps companies fund the research for their next blockbuster drug as well as the expenses required to operate a growing healthcare company.

The Belgian group specialises in the research of novel drugs based on nano - bodies found in the immune systems of llamas and alpacas, for which it partners with several of the world's largest pharmaceutical companies.

The Danish company said it would pay 28.00 euros per share in cash for Ablynx and an additional 2.50 euros in a so - called contingent value right (CVR) if certain conditions related to other drugs in Ablynx's research portfolio were met.

Those savings would be such a boon to Teva, it would be as if the company had launched another blockbuster drug, «with exclusivity extending into perpetuity,» analysts at investment back Cowen wrote in a research note.

But a funny thing happened as the company took on projects (research on the deaf as well as on drug use and AIDS) further and further afield from its initial market.

«Her breadth of experience in biomedical research and development can benefit Exelixis greatly as the company recommits its resources to drug discovery and bolstering its pipeline following the successful ongoing commercialization of its lead medicine, CABOMETYX.»

Eagle's Sassouni pointed out that since the big drug companies are losing billions of dollars every year to generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology companies that are developing their own products.

In fact, if you believe Ackman's math, Valeant goes from one of the industry's stingiest companies when it comes to R&D, as critics contend, to one of the biggest spenders on drug research.

And Valeant's round - about method of funding research, if that's what it's actually doing, seems a lot less cost effective, with all of the bankers and lawyers and hedge fund managers taking chunks of deals than if drug companies directly devoted a portion of their sales toward finding new drugs.

Perhaps this will include research and development of drugs for other diseases, albeit with fewer researchers, but to date, neither the amount the company will save nor its specific use of these freed - up resources has been detailed.

In 2017, according to Deloitte, the 12 largest bio - pharma companies got a mere 3.2 % return out of their drug - research arms.

The company had to abandon the research due to funding shortfalls before the drug could be fully tested.

The company focuses on cancer drug research and has a platform for so - called «real - world» data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.

Pharmaceutical companies research hundreds of molecular groups before coming up with a marketable drug.

Andrew's primary responsibility at RA Capital is to evaluate public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, with a focus on new company formation.

SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.

These companies tend to have more dependable streams of revenue and a more diversified «pipeline» of drugs in the research and development stages, making them less dependent on make - or - break drug trials and their shares less volatile.

«You don't like companies doing drug research and market based pricing?

This increased survival rate places a high value on immunotherapy drugs and the companies that research and produce them.

Pharmaceutical company deals are motivated by the desire to beef up the new drug pipeline and streamline heavy research costs.

But what Sequoia married itself to was an offshore drug company that borrowed heavily to buy other drug companies, cut costs and research, then raised prices on many older drugs to astronomical heights.

Early Monday, Allergan plc Ordinary Shares (NYSE: AGN)-- one of the world's largest pharmaceutical companies that produces branded and generic drugs, and performs pharmaceutical research and development — announced its recent acquisition of Zeltiq Aesthetics.

«This was literally a drug company that was doing no [research and development].

That may come as a surprise amid hand - wringing about the spiraling cost of health care, but two new studies, one from research company IMS Health and one from pharmacy benefit manager Express Scripts, show that the amount of money Americans spend on prescription drugs went down in 2012 for the first time in decades.

Stocks of the aforementioned drug companies should be researched for both their takeover potential (specifically INHX, IDIX, and ACHN) by larger companies like Merck, Bristol Myers (BMY) and Johnson & Johnson (JNJ - Free Johnson & Johnson Stock Report).

Accordingly, some drug manufacturers, flush with cash, attempt to acquire smaller companies — and their pipeline of drugs under research and development.

Companies that provide drug development and other product development services, equipment, software and services for research, manufacturing discovery and medical diagnostics.

-RRB- are contracted out by large drug companies to efficiently and comprehensively perform research on their products and help them bring the drug to market.

Pharmaceutical Research and Manufacturers of America, or PhRMA, the trade group that advocates for drug companies, spent almost $ 10 million on lobbying in the first quarter of 2018, according to the Center for Responsive Politics.

That cash doesn't include the money PhRMA's spending on the ongoing «Go Boldly» campaign, a series of TV, print and radio ads designed to polish the drug industry's image by reminding the public that drug companies do world - class research that brings disease cures to market to save lives.

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday's after - hours trading sessions, after the medical research and drug development company crushed earnings estimates.

Nevertheless, when one reads, for instance, of how the Eli Lilly company used homeless alcoholics for testing experimental drugs, it is hard not to believe that such guinea pigs are being exploited, even if they may welcome their improved living conditions during the course of the research.

Pharmaceutical companies have needed to test more and more potential drugs, the tests (and the regulations that govern them) have become increasingly complicated, and the companies, whose research costs are enormous, have required a faster pace than the academy can provide.

for stem cell research, there are tons of investors, it's just that the drug companies stand to lose millions and they have deeper pockets so they can bribe who they want to make sure it stays illegal.

As for stem cell research, I don't think you understand the reach of these big drug companies.

And for stem cell research, there are tons of investors, it's just that the drug companies stand to lose millions and they have deeper pockets so they can bribe who they want to make sure it stays illegal.

One serious problem in the area of recombinant DNA research is, however, that drug companies and government agencies are as much involved as are university professors.

Medical research must be funded in some way, and if it's funded by cosmetic companies, I honestly sometimes think that's better than it being funded by drug companies who push pill after pill regardless of the consequences.

The FDA is suppose to monitor «research» on food and drugs and yet is largely funded by the pharmaceutical companies.

first as a research analyst in a large Pharmaceutical company — working with off licence immuno suppressive drugs and latterly as... Continue reading →

The model is the basis of the state's first Buffalo Billion project, in which the state is providing $ 50 million to build and equip a facility at or near the downtown Buffalo Niagara Medical Campus to attract companies involved in pharmaceutical drug research and manufacturing.

New York State was planning to invest in a new facility in Buffalo for a drug discovery company, Albany Molecular Research Inc., and the medical campus was being invited to partner.

This time I also requested records documenting the selection of LP Ciminelli and Ciminelli Real Estate — separate companies owned by brothers — to build space at the Conventus Building on the Buffalo Niagara Medical Campus to accommodate AMRI, a drug research and development firm recruited with $ 50 million in Buffalo Billion money.

He added that many drug companies have stopped their research into finding new medicines for epilepsy.